Ideaya Biosciences Inc Asset Resilience Ratio
Ideaya Biosciences Inc asset resilience ratio. Ideaya Biosciences Inc (IDYA) has an Asset Resilience Ratio of 42.48% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IDYA defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Ideaya Biosciences Inc (2017–2025)
Asset resilience ratio of Ideaya Biosciences Inc from 2017 to 2025. This chart shows how Ideaya Biosciences Inc's Asset Resilience Ratio has changed over time. Read Ideaya Biosciences Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Ideaya Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Ideaya Biosciences Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $556.37 Million | 42.48% |
| Total Liquid Assets | $556.37 Million | 42.48% |
Asset Resilience Insights
- Very High Liquidity: Ideaya Biosciences Inc maintains exceptional liquid asset reserves at 42.48% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Ideaya Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Ideaya Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Ideaya Biosciences Inc Asset Resilience Ratio by Year (2017–2025)
Ideaya Biosciences Inc asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Ideaya Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 47.47% | $526.56 Million | $1.11 Billion | -5.19pp |
| 2024-12-31 | 52.66% | $591.94 Million | $1.12 Billion | -4.03pp |
| 2023-12-31 | 56.69% | $368.10 Million | $649.32 Million | -19.66pp |
| 2022-12-31 | 76.35% | $296.20 Million | $387.97 Million | +35.77pp |
| 2021-12-31 | 40.57% | $154.72 Million | $381.35 Million | -30.35pp |
| 2020-12-31 | 70.93% | $211.55 Million | $298.27 Million | +13.50pp |
| 2019-12-31 | 57.42% | $64.89 Million | $113.00 Million | -14.52pp |
| 2018-12-31 | 71.94% | $69.46 Million | $96.54 Million | +30.78pp |
| 2017-12-31 | 41.17% | $7.20 Million | $17.48 Million | -- |
About Ideaya Biosciences Inc
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and … Read more